Latest Ratios: P/E Ratio -7.5x · EV/EBITDA N/A · ROE -49.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.7B | $2.6B | $1.3B | $975M | $937M | $236M | $59M | $15M | $90M | $201M | $54M |
| Enterprise Value | $2.5B | $2.5B | $1.2B | $893M | $787M | $194M | $13M | $-1500523 | $67M | $163M | $52M |
| P/E Ratio → | -7.53 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 103.03 | 37.25 | 4309.19 | 3104.38 | 528.93 | 79.53 | 55.73 | 3.37 | 10.70 | 50.14 | 16.25 |
| P/B Ratio | 3.54 | 3.65 | 1.94 | 2.21 | 2.37 | 1.26 | 0.49 | 0.95 | 1.75 | 5.21 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 34.97 | 4049.26 | 2843.93 | 444.10 | 65.60 | 12.45 | -0.34 | 8.03 | 40.77 | 15.56 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2595.6% | 100.0% | -262.8% | -390.2% | 23.6% |
| Operating Margin | -512.9% | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% | -10512.4% | -941.0% | -394.5% | -662.8% | -374.8% |
| Net Profit Margin | -483.6% | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -662.3% | -379.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.2% | -49.2% | -48.5% | -56.8% | -44.6% | -51.6% | -163.1% | -124.8% | -72.8% | -138.9% | -251.4% |
| ROA | -41.7% | -41.7% | -43.8% | -51.4% | -40.7% | -47.4% | -137.1% | -86.9% | -55.1% | -93.5% | -147.7% |
| ROIC | -47.3% | -47.3% | -47.0% | -63.1% | -51.5% | -54.1% | -224.3% | -222.9% | -165.3% | -2008.0% | — |
| ROCE | -47.7% | -47.7% | -51.6% | -58.8% | -45.4% | -51.3% | -156.9% | -105.6% | -61.3% | -110.0% | -247.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.03 | 0.05 | 0.01 | 0.01 | 0.00 | 0.53 | 0.20 | 0.26 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.12 | -0.19 | -0.38 | -0.22 | -0.38 | -1.05 | -0.43 | -0.97 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -68.24 | -68.24 | -87.62 | -127.71 | -266.23 | -26470.00 | -79.76 | -49.15 | -36.46 | -68.22 | -132.41 |
Net cash position: cash ($212M) exceeds total debt ($51M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.65 | 12.65 | 15.43 | 18.26 | 12.73 | 14.68 | 12.14 | 2.92 | 9.71 | 13.31 | 0.93 |
| Quick Ratio | 12.65 | 12.65 | 15.43 | 18.26 | 12.93 | 14.68 | 12.14 | 2.92 | 9.71 | 13.31 | 0.91 |
| Cash Ratio | 12.37 | 12.37 | 14.99 | 17.92 | 12.73 | 14.44 | 11.96 | 2.64 | 9.28 | 12.17 | 0.73 |
| Asset Turnover | — | 0.08 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.15 | 0.13 | 0.08 | 0.78 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 39.81 |
| Days Sales Outstanding | — | — | — | 118.57 | 21.01 | 55.56 | — | 8.84 | 1.04 | 132.76 | 57.31 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Shares Outstanding | — | $85M | $68M | $45M | $32M | $12M | $4M | $2M | $2M | $1M | $721410 |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VRDN stock.
Viridian Therapeutics, Inc.'s current P/E ratio is -7.5x. This places it at the 50th percentile of its historical range.
Viridian Therapeutics, Inc.'s return on equity (ROE) is -49.2%. The historical average is -111.0%.
Based on historical data, Viridian Therapeutics, Inc. is trading at a P/E of -7.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Viridian Therapeutics, Inc. has 100.0% gross margin and -512.9% operating margin.
Key Metrics
Top Statement Risk
Cash runway versus Phase 3 funding
Metrics are mathematically derived from official filings.
Premium Pricing Ahead of Commercial Proof
Based on reported figures, VRDN trades at a P/S of 36.19 and P/B of 3.35 with a negative trailing P/E of -8.58, a multiple structure that prices in future Lumvoa commercial success rather than current earnings power or cash generation.
Compared with its own history, the price-to-sales multiple appears elevated because the revenue denominator is driven by lumpy milestone recognition rather than recurring product sales. Relative to peers such as IMVT at 6.53x P/B and KYMR at 7.04x, VRDN's 3.35x P/B looks comparatively restrained, suggesting the market is not yet assigning a full premium on book value. Investors should monitor whether early Lumvoa revenue growth can justify the growth expectations embedded in these multiples.
Milestone Revenue Masks Operating Losses
As reported in financial statements, VRDN posted a 2026Q3 operating margin of -4.0% but operating margins of -444.6% and -823.9% in the prior two quarters, showing that single-quarter profitability readings are highly sensitive to milestone timing.
The 94.1% to 100% gross margins reflect milestone accounting without offsetting manufacturing costs, so they carry little analytical weight for true earning power. Operating losses scaled with R&D spend, as the trailing operating margin of -512.9% indicates a cost base far exceeding recognized revenue. The more informative measure of earning power is the sustained operating loss of roughly $100M to $125M per quarter, which warrants close tracking as Lumvoa scales.
Negative Returns Reflect Continued Capital Consumption
According to recent filings, VRDN's ROE ranged from -6.8% to -19.6% and ROIC from -7.7% to -20.1% across the ten quarters, indicating returns on invested capital that have been consistently negative rather than compounding.
The pattern shows no sustained improvement in ROIC despite the asset base expanding from $585.7M to $1.0B, suggesting new capital is funding R&D rather than productive earning assets. Return metrics are driven primarily by the operating loss rather than by capital efficiency, so the margin problem and the capital problem are effectively the same problem. Until operating losses narrow materially, return metrics are unlikely to turn positive.
Debt Rising From a Low Base
Based on EDBL's reported figures, VRDN's debt-to-equity ratio climbed from 0.04 a year earlier to 0.42 at 2026Q3, with total debt of $243.3M, a rise that is modest in absolute terms but steep in relative direction.
Interest coverage is deeply negative at -10.94x in 2026Q3 and has been negative throughout the reported window, meaning current earnings provide no debt service capacity and obligations appear to be met from the cash balance. The rapid increase in leverage appears to coincide with balance sheet expansion funded externally, so debt service expectations should be tracked against reported quarterly cash outflows. The absence of a reported debt maturity profile in the supplied data limits assessment of refinancing exposure.
Strong Current Ratio Versus Burn Reality
As reported in financial statements, VRDN's current ratio of 14.46 at 2026Q3 and $172.9M in cash appear strong on paper, but quarterly operating outflows of roughly $90M to $125M suggest the liquidity buffer could be consumed within a few quarters.
The current ratio of 14.46 is driven by short-term assets that likely include cash and clinical-stage receivables, and it does not account for planned Phase 3 spending on THRIVE and THRIVE-2. Under a stress scenario where milestone revenue fails to recur, the cash position would likely require additional equity raises to maintain trial timelines. This suggests the liquidity position warrants further investigation against the company's disclosed runway guidance, which is not included in the supplied data.
Price-to-Sales Misreads Milestone-Driven Revenue
Based on reported figures, the 36.19 P/S multiple is most commonly misapplied to VRDN because revenue is milestone-timed rather than recurring, so the ratio overstates the sales-based premium the market is actually paying for the pipeline.
Applying a sales multiple to a company whose revenue swung from near-zero to $70.6M and back to $25.8M obscures the fact that the market is valuing the Lumvoa franchise and pipeline rather than current sales. A more appropriate lens is cash burn-adjusted enterprise value per dollar of risk-adjusted peak sales, along with runway months from the $172.9M cash balance. This suggests investors should monitor clinical milestones and funding timing rather than anchor on trailing P/S.